Objectives While exercise adherence is known to vary during cancer treatment, little is known about what predicts these changes during chemotherapy or within individual treatment cycles for breast ...
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth ...
Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II ...
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in ...
The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)—a large-scale, phase III ...
ALTOONA, Pa. (WTAJ) — Cancer patients in Central Pennsylvania now have greater access to an advanced prostate cancer treatment with the launch of Pluvicto at UPMC Altoona. Beginning in April, UPMC ...
Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT ...
AstraZeneca (AZN) stock is in focus as FDA panel snubs the company's bid to win U.S. nod for camizestrant and backs its ...
Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak ...
Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” ...
An FDA advisory panel voted 7-1, with one abstention, to endorse AstraZeneca’s capivasertib plus abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer. The CAPItello-281 ...
Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2026, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results